Biden ad­min­is­tra­tion lays foun­da­tion for use of march-in rights as it talks up drug price goals

The De­part­ment of Com­merce on Thurs­day re­leased new draft frame­work which guides the gov­ern­ment to con­sid­er pric­ing in de­cid­ing whether to use its au­thor­i­ty to take over patents on pre­scrip­tion drugs that were in­vent­ed with the help of fed­er­al­ly-fund­ed re­search.

Pres­i­dent Joe Biden hailed the frame­work as “an im­por­tant step to­ward end­ing Big Phar­ma price goug­ing” in a post on X, the so­cial me­dia plat­form for­mer­ly known as Twit­ter. But in­dus­try ad­vo­cates ar­gue the move could have a chill­ing ef­fect on in­no­va­tion, de­pend­ing on how the gov­ern­ment pro­ceeds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER